From Teesside Uni to global leader

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jarlath Keating President & CEO at ABL Inc. Jarlath has over 25 years of global life science industry experience. Starting his career in the UK in the early 90’s before transitioning to the US in 2009. During this time, Jarlath worked for HyClone and Lonza Biologics. He served as the Vice President of Global Commercial Operations for MilliporeSigma’s Process Solutions Services division, leading the BioReliance® biological safety testing and biomanufacturing divisions. He now leads ABL, globally. Your host, Raman Sehgal, leads a conversation on the pharmaceutical and biotechnology supply chain, transitioning from ‘shop floor’ to CEO, and the impact of COVID-19 from a manufacturing point of view. Hear Jarlath’s thoughts on:     The importance of leaders building knowledge across the whole business.     Understanding the jigsaw - your success is dependent upon the success of your colleagues.     Taking opportunities, leaning into risk, and backing yourself through belief and hard work.     The evolution of the gene therapy and cell therapy space, and the operational challenges it brings.     How contract service providers must anticipate rather than react to future pandemics and new areas of development. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.